Ezekowitz Alan

SEC source: 0001193125-26-294680 · ownership.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2036-06-29

F1 · derivative.exercise_date: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001193125-26-291050 · ownership.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0001193125-26-290622 · ownership.xml · nonDerivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,927

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001628280-26-043224 · wk-form4_1781555609.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,141.131

Underlying: Common Stock · 17,857.143 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026.

SEC source: 0000950170-25-091577 · ownership.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2035-06-25

F1 · derivative.exercise_date: This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000950170-25-088615 · ownership.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,623

Underlying: Common Stock · 16,623 shares

Expires 2035-06-16

F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0001821825-25-000045 · wk-form4_1750108854.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,702.653

Underlying: Common Stock · 23,904.382 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025.

SEC source: 0000950170-25-036321 · ownership.xml · nonDerivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,420

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.61 to $7.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0000950170-25-035064 · ownership.xml · nonDerivative · entry 3

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,101

F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.82 to $6.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0000950170-25-035064 · ownership.xml · nonDerivative · entry 2

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,746

F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.68 to $6.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0000950170-25-035064 · ownership.xml · nonDerivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,911

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.40 to $6.44. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0000950170-24-074892 · ownership.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-06-16

F1 · derivative.exercise_date: This option was granted on June 17, 2024 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001821825-24-000078 · wk-form4_1718133454.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,454.814

Underlying: Common Stock · 9,638.554 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024.

SEC source: 0000950170-23-030755 · ownership.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-26

F1 · derivative.exercise_date: This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001209191-23-036769 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,285

Underlying: Common Stock · 10,086 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023.

SEC source: 0000899243-22-024528 · doc4.xml · derivative · entry 2

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,500

Underlying: Common Stock · 500 shares

Expires 2030-12-02

F2 · derivative.exercise_date: No value was received for the cancellation of these stock options, which were originally granted on December 3, 2020.

SEC source: 0000899243-22-024528 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2032-06-26

F1 · derivative.exercise_date: This option was granted on June 27, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001104659-22-071134 · tm2218336-2_4seq1.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,638

Underlying: Common Stock · 5,640 shares

Expires not disclosed

F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022.

SEC source: 0000899243-21-023285 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-21-022682 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,772

Underlying: Common Stock · 8,772 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.

F2 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.

SEC source: 0000899243-20-032868 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-12-02

F1 · derivative.exercise_date: This option was granted on December 3, 2020 and is scheduled to vest with respect to all shares on November 2, 2021, subject to continued service.

SEC source: 0000899243-20-016498 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,285

Underlying: Common Stock · 9,285 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001104659-19-040970 · a4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,714

Underlying: Common Stock · 5,714 shares

Expires 2029-07-17

F1 · derivative.exercise_date: The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest on July 18, 2020 or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.